Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ruxolitinib
100%
Acute Myeloid Leukemia
66%
Urothelial Bladder Cancer
66%
Polycythemia Vera
66%
Best Medical Treatment
51%
High Risk
43%
Well Tolerated
38%
Hydroxycarbamide
37%
Ibrutinib
33%
Azacitidine
33%
Myelodysplastic Syndrome
33%
COVID-19 Vaccination
33%
Clinical Significance
33%
Non-invasive Diagnosis
33%
Invasive Risk
33%
Gene Panel
33%
Biological Relevance
33%
Targeted Deep Sequencing
33%
Urinary DNA
33%
Venetoclax
33%
Intensive Chemotherapy
33%
Somatic mutation
33%
Low-grade Urothelial Carcinoma
33%
Chronic Lymphocytic Leukemia
33%
Risk Stratification
33%
Non-synonymous mutation
33%
Clinical Potential
33%
Romidepsin
33%
T Cells
33%
Non-muscle Invasive Bladder Cancer (NMIBC)
33%
Randomized Trial
33%
Intolerant
33%
Recurring
33%
Blood Cancer
33%
Plain Language Summary
33%
Lack of Response
33%
Myelofibrosis
33%
Bromodomain
33%
Phase Ib Study
33%
COVID-19
33%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
33%
Relapsed/refractory Chronic Lymphocytic Leukemia
33%
Interim Analysis
33%
Recurrence Rate
25%
Intermediate Risk
22%
Recurrence-free Survival
22%
Recurrence-free Interval
22%
Event-free Survival
20%
Minimal Residual Disease
19%
Cell-free DNA (cfDNA)
18%
Pharmacology, Toxicology and Pharmaceutical Science
Ruxolitinib
100%
Azacitidine
66%
Polycythemia vera
66%
Myelofibrosis
66%
Hydroxycarbamide
40%
Diseases
38%
Monotherapy
38%
Chemotherapy Regimens
37%
Phase II Trials
36%
Myeloproliferative Neoplasm
36%
Ibrutinib
33%
Clinical Trial
33%
Obinutuzumab
33%
Tamoxifen
33%
Acute Myeloid Leukemia
33%
Romidepsin
33%
Eltrombopag
33%
Myelodysplastic Syndrome
33%
Malignant Neoplasm
33%
Clinical Study
33%
Fedratinib
33%
Ropeginterferon Alpha2b
33%
Tolerability
33%
Remission
30%
Maximum Tolerated Dose
27%
Adverse Event
20%
Event Free Survival
20%
Disease Exacerbation
15%
Splenomegaly
15%
Preclinical Study
13%
Overall Survival
12%
Phase III Trials
11%
Phosphotransferase
11%
Janus Kinase 2 Inhibitor
11%
Side Effect
11%
Thrombocytopenia
8%
Cerebrovascular Accident
7%
Neoplasm
6%
Progression Free Survival
6%
Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone)
6%
Afimoxifene
6%
Janus Kinase
6%
Therapy Resistance
6%
Transcriptome
6%
JAK-STAT Signaling
6%
Histone Deacetylase Inhibitor
6%
Lymphadenopathy
5%
Interferon
5%
Peginterferon
5%
Myeloid metaplasia
5%
Medicine and Dentistry
Acute Myeloid Leukemia
66%
Myelodysplastic Syndrome
66%
Azacitidine
66%
Ibrutinib
33%
Venetoclax
33%
Risk Stratification
33%
Non Invasive Measurement
33%
Somatic Mutation
33%
Romidepsin
33%
Bladder Cancer
33%
Urinary System
33%
B-Cell Chronic Lymphocytic Leukemia
33%
Eltrombopag
33%
Ruxolitinib
33%
Clinical Study
33%
Myelofibrosis
33%
Interim Analysis
33%
Chemotherapy
33%
Severe Acute Respiratory Syndrome
22%
Acute Myelogenous Leukemia
22%
Diseases
18%
Minimal Residual Disease
14%
Overall Survival
13%
Platelet
12%
Tumor
12%
Adverse Event
11%
COVID-19 Vaccination
11%
COVID-19
11%
Omicron Coronavirus Variant
11%
Neutralization
11%
Prospective Study
11%
Disease Model
11%
T Cell
11%
Cohort Effect
11%
T-Cell Response
11%
Antigen
11%
Splenomegaly
10%
Palpation
10%
Combined Therapy
8%
Thrombocytopenia
8%
Progression Free Survival
7%
Histone Deacetylase Inhibitor
6%
International Prognostic Scoring System
6%
Therapy Resistance
6%
In Vitro
6%
Next Generation Sequencing
6%
Gene Frequency
6%
Promoter Region
6%
